Advanced search×

Resource use and costs of type 2 diabetes in Sweden - estimates from population-based register data.

A Ringborg, M Martinell, J Stålhammar, D D Yin, and P Lindgren

Int J Clin Pract 62(5):708-16 (2008) PMID 18355236

To examine medical resource use of Swedish patients with type 2 diabetes during 2000-2004 and to estimate annual costs of care.

DOI: 10.1111/j.1742-1241.2008.01716.x
Version: za2963e q8za6 q8zb1 q8zc1 q8zd2 q8ze4 q8zf1 q8zga

Similar articles you may find interesting…

  1. Insulin therapy to improve BMI in cystic fibrosis-related diabetes without fasting hyperglycemia: results of the cystic fibrosis related dia...
    Antoinette A Moran, Penelope P Pekow, ...

    Audio, Transactions of the IRE Professio... 32(10):1783-8 (2009) PMID 19592632

    Insulin therapy safely reversed chronic weight loss in patients with CFRD FH-....
  2. Impact of metformin versus the prandial insulin secretagogue, repaglinide, on fasting and postprandial glucose and lipid responses in non-ob...
    Søren S Lund, Lise Tarnow, ... Allan A Vaag

    Eur J Endocrinol 158(1):35-46 (2008) PMID 18166815

    In non-obese T2DM patients, metformin reduced postprandial levels of glycaemia, triglycerides and FFA similarly compared to the prandial insulin secretagogue, repaglinide. Furthermore, metformin reduced fasting and postprandial cholesterolaemia and insulinaemia compared with repaglinide. These data...
  3. Cardiometabolic effects of rosiglitazone in patients with type 2 diabetes and coronary artery bypass grafts: A randomized placebo-controlled...
    Olivier F Bertrand, Paul Poirier, ... VICTORY Trial Investigators

    Atherosclerosis 211(2):9 (2010) PMID 20594555

    We found no evidence for a statistically significant effect of rosiglitazone on SVG atherosclerosis whereas significant effects on glycemic control and on the cardiometabolic risk profile appeared to be modulated in part by changes in subcutaneous adiposity. Copyright 2010 Elsevier Ireland Ltd. All...